GLP-3 RTA [Triple G] – 50mg

GLP-3 RTA (Triple G) is a triple incretin receptor agonist research peptide simultaneously targeting glucagon like peptide 1 (GLP-1), glucose dependent insulinotropic polypeptide (GIP), and glucagon receptors; representing the most advanced incretin based research compound in CSD’s metabolic peptide range. Hudson Science’s 50mg formulation delivers a lower concentration presentation than the 60mg GLP-3 RTA variant as a lyophilized vial, providing researchers with a more accessible entry point into triple incretin agonist research or a practical option for shorter duration protocols where the full 60mg supply volume is not required.

The triple receptor mechanism of GLP-3 RTA remains consistent across both concentration presentations. GLP-1 receptor activation drives glucose dependent insulin secretion, glucagon suppression at the pancreas, and central nervous system satiety signaling. GIP receptor activation contributes complementary insulinotropic activity alongside adipose tissue metabolic effects and bone turnover research applications. Glucagon receptor co activation adds direct hepatic glucose output regulation, thermogenic energy expenditure stimulation, and lipolytic activity in adipose tissue, a third distinct pathway that produces a synergistic metabolic response beyond what dual incretin agonism alone achieves and has driven significant research interest in comparative receptor pathway studies.

The 50mg and 60mg GLP-3 RTA presentations from Hudson Science sit at the top of CSD’s incretin agonist research family above the dual GIP/GLP-1 agonist GLP-2 TRZ 20mg and GLP-2 TZ 15mg listings in receptor pathway complexity. Concentration selection between the two Triple G variants comes down to protocol length and dose response requirements, with the 60mg format suited to extended timelines and the 50mg format providing a practical option for shorter protocols or initial compound evaluation before committing to larger supply volumes.

Every batch of Hudson Science’s GLP-3 RTA is third party lab tested for concentration accuracy and purity prior to release, with COA documentation available on request. Canada Steroid Depot has supplied Canadian customers with consistently verified, accurately dosed research compounds for years, and our incretin agonist range represents the most comprehensive metabolic peptide sourcing available from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.

Reconstitute with bacteriostatic water prior to use. Store lyophilized peptide at 2–8°C away from direct light. Once reconstituted refrigerate and use within 28 days. Intended for research purposes only.

Commonly researched alongside dual incretin agonist compounds in comparative receptor pathway and metabolic activity studies. Browse CSD’s full peptide range for complete sourcing.